ReoPro cuts angioplasty complications in half:
This article was originally published in Clinica
Centocor's antithrombotic drug ReoPro cut heart attacks and death six months after angioplasty by 46% in the EPILOG trial (Evaluation of PTCA to Improve Long-Term Outcome by c7E3 GP IIb/IIIa Receptor Blockade). At the same time it reduced the need for emergency revascularisation by 53.7%, said chairman of the Cleveland Clinic's cardiology department Dr Eric Topol. ReoPro inactivates IIb/IIIa binding sites on the surface of blood platelets.
You may also be interested in...
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.